Prediabetes

Amrit Lamba considers the rather mixed results of the PREVIEW project, and what they mean for primary care (3:40).

Losing weight in the CAMELLIA-TIMI 61 trial was associated with a significantly reduced risk for developing type 2 diabetes, the investigators have reported at the 54th EASD Annual Meeting in Berlin, Germany.

LeBlanc ES et al. Diabetes Care 2019. doi: 10.2337/dc18-0240

Jiang L et al. Diabetes Care 2018; 41: 1462–1470. doi: 10.2337/dc17-2685

Thankappan KR et al. PLoS Med 2018; 15: e1002575. doi: 10.1371/journal.pmed.1002575

Interleukin-1 beta inhibition with canakinumab does not prevent the development of type 2 diabetes, a secondary analysis of data from CANTOS shows.

Honsek C et al. Diabetologia 2018; Advance online publication. doi: 10.1007/s00125-018-4582-6

Editorial Board member John Wilding highlights the current evidence for the benefits of physical activity across various domains of type 2 diabetes care and prevention, presenting his view of what should be recommended.

Saslow LR et al. Nutr Diabetes 2017; 7: 304. doi: 10.1038/s41387-017-0006-9

A meta-analysis shows that although medications and lifestyle changes can both reduce the risk for type 2 diabetes in high-risk patients, only lifestyle modifications have a sustained effect.

Liraglutide enhances the positive effects of lifestyle intervention on weight loss and glycemic control in patients with prediabetes, show the 3-year outcomes of the SCALE Obesity and Prediabetes trial.